Rituximab Retreatment Can Produce Prolonged Failure-Free Survival for Relapsed Indolent B-cell Lymphoma

Publication
Article
OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

The efficacy and toxicity of readministration of rituximab (Rituxan) in patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that recurs after an initial response to rituximab are unknown.

The efficacy and toxicity of readministration of rituximab (Rituxan) in patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that recurs after an initial response to rituximab are unknown. We conducted a multicenter, phase II study of rituximab in indolent CD20-positive B-cell NHL. The present study attempts to investigate the safety and efficacy of readministration of rituximab.

From July 1997 to November 1998, patients with relapsed, indolent, CD20-positive B-cell NHL, revised European-American Lymphoma (REAL) type II-1, 2, 3, 4, 5, and 6 histology, all of whose pathology was confirmed by central review, were treated with rituximab at 375 mg/m² × 4 weekly infusions as a phase II study in Japan. Rituximab produced a 59% response rate (95% confidence interval [CI], 41% to 71%) Retreatment was planned for responsive patients who showed stable disease (SD), partial response (PR), or complete response (CR) after the initial treatment. To be eligible for retreatment, patients were required to meet the same criteria as for a phase II study.

Nine patients were retreated with identical courses of rituximab. Five patients who received rituximab (250 or 375 mg/m² × 4 weekly infusions) in the preceding phase I study were also entered into this study. All 14 patients eligible for retreatment had stage IIIA or IVA disease and had an International Prognostic Index (IPI), placing them in a low- or low-intermediate risk group. The median follow-up time was 19 months (range, 15 to 33 months). Of the 14 patients, 11 had follicular lymphoma; 1, mantle cell lymphoma; and 2, diffuse large B-cell lymphoma.

Rituximab retreatment was well tolerated, with no grade 3-4 nonhematologic toxicity, similar to initial therapy. One patient developed grade 3 neutropenia. One patient died of disease progression. All patients experienced rapid B-cell decrease, which lasted for more than 4 months. No patient developed human antimouse antibody (HAMA) and human antichimeric antibody (HACA) reactions after retreatment. T-cell counts and serum immunoglobulin levels did not decrease during the follow-up period.

Responses to retreatment were seen in 5 of 14 patients (36%; 95% CI,12% to 64%); 7patients had SD; and 2 experienced progressive disease (PD). Overall survival rate was 93% at 19 months. Median time to progression (TTP) after retreatment was 5 months, while median TTP after initial treatment was 8 months.

There was no significant correlation between TTP after initial treatment and that after the second treatment. Three patients who received more than three courses of retreatment continue to show response.

CONCLUSION: Rituximab is effective for relapsed, indolent, CD20-positive B-cell NHL after initial rituximab treatment and can produce prolonged failure-free survival without major toxicities.

Click here for Dr. Bruce Cheson’s commentary on this abstract.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
A panel of 4 experts on multiple myeloma
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Related Content